Aerosure and Six Minute Walk Distance in Severe COPD
Launched by ACTEGY LTD. · Dec 6, 2013
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stable severe COPD (FEV1 \< 50% predicted)
- • Modified MRC dyspnoea score 2 or greater
- • At least 10 pack year smoking history
- • Able to mobilise independently
- Exclusion Criteria:
- • Contraindications to spirometry \[1\]
- • Contraindications to clinical exercise testing \[2\]
- • Contraindications to HFAO (see section A.6.3b))
- • Resting SpO2\>88% on air or on patient's usual oxygen prescription
- • Systolic arterial blood pressure (ABP) \>200mmHg, diastolic ABP \>100 mmHg
- • 1. Cooper, B.G., An update on contraindications for lung function testing. Thorax, 2010.
- • 2. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am. J. Respir. Crit. Care Med., 2003. 167(2): p. 211-277.
About Actegy Ltd.
Actegy Ltd. is a pioneering clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a focus on medical technologies and therapeutic interventions, Actegy leverages cutting-edge methodologies to design and conduct clinical trials that prioritize patient safety and efficacy. The company collaborates with a network of healthcare professionals and institutions to facilitate the development of products that enhance patient outcomes and improve quality of life. Committed to ethical standards and regulatory compliance, Actegy Ltd. strives to drive scientific progress and contribute to the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
John Moxham, MD
Principal Investigator
King's College Hospital NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials